/Investor DB

Lilly Ventures — Full Portfolio

14 tracked investments · listed companies and verified rows first

BioAge Labsbioagelabs.comin𝕏NASDAQ: BIOAFeb 2024

BIOAGE develops therapies targeting the molecular pathways that drive aging to increase healthspan and address age-related chronic diseases.

BiotechHealthtechLongevityRichmond, US

Kristen Fortney, PhD(Co-Founder, CEO)Eric Morgen, MD(Co-Founder, COO)Kristen Fortney(Executive Officer, Director)inEric Morgen(Director)inDov Goldstein(Executive Officer)in

BoardPatrick Enright(Director)in

Co-investorsAndreessen HorowitzElad GilFelicis VenturesGreen Sands EquityIA Seed VenturesLongitude Capital+20 more

Dare Biosciencedarebioscience.comin𝕏NASDAQ: DARE

Daré Bioscience is a female-led biotech company developing treatments for women's health conditions that are overlooked in the healthcare industry.

BiotechDigital HealthDirect to ConsumerFemTechHealthtechSan Diego, US

MarDee Haring-Layton(Chief Accounting Officer)inSabrina Martucci Johnson(Founder & Chief Executive Officer)Christopher D.T. Guiffre(Executive Officer, Director)Gregg Beloff(Executive Officer)Alejandra V. Carvajal(Executive Officer)Adrian Senderowicz(Executive Officer)

Co-investorsPolaris PartnersVenrock

Protagonist Therapeuticsprotagonist-inc.comin𝕏NASDAQ: PTGXJul 2015 · $14M

Protagonist is a company that emphasizes a diverse and inclusive corporate culture as central to its innovation, with stated goals of creating wins for its organization and for patients.

BiotechHealthtechMilpitas, US

Dinesh V. Patel, PhD(Executive Officer, Director)Dinesh Patel(President & Chief Executive Officer)

BoardAsish K. Xavier, Ph.D.(Director)Michael Panaccio, Ph.D.(Director)Armen Shanafelt, Ph.D.(Director)Paul F. Truex(Director)

Co-investorsAisling CapitalCanaan PartnersJJDCJohnson & Johnson Innovation – JJDCRA CapitalStarfish Ventures

Ceruleanjoincerulean.comin𝕏

Cerulean builds AI agents that automate high-value business processes and improve productivity for organizations.

AI & Machine LearningEnterprise SoftwareSaaSSector Agnostic

Kieran Luke(Founder)in

Co-investorsMastryMosaic General Partnership, LLCBessemer Venture PartnersLux CapitalVenrock

Hydra Bioscienceshydrabiosciences.com

BiotechCambridge, US

Magdalene Moran, Ph.D.(Executive Officer)Bert Chenard, Ph.D.(Executive Officer)Russell Herndon(Executive Officer, Director)Tom Burke(Executive Officer)

BoardVincent Miles(Director)Jean George(Director)

Co-investorsLightstone VenturesNew Enterprise Associates (NEA)Saints CapitalAbingworth

Longevitylongevity.foundationin𝕏Jun 2026 · $435M

The Longevity Science Foundation funds scientific research to address the biological drivers of women's health disparities, particularly ovarian aging and menopause.

BiotechHealthtechImpact & Social GoodLongevityZug, CH

Joshua C. Herring(President & CEO)in

Co-investorsLongeVCFounders FundKhosla VenturesThrive Capital

Longevitylongevityhealthplan.comJun 2026 · $435M

Longevity Health provides health insurance plans focused on optimizing quality of life for people in long-term care through value-based, personalized solutions addressing physical, mental, emotional, and social well-being.

Digital HealthHealthtechInsurTechLongevity

BoardRené Lerer(President of Guidewell Mutual Holding Company)

Co-investorsK2 HealthVenturesAhren Innovation CapitalFounders FundKhosla VenturesLightspeed Venture PartnersNestle+1 more

Lysosomal Therapeuticslysosomaltx.org

Lysosomal Therapeutics Inc.

BiotechCambridge, US

Dimitri Krainc(Director)Robert Carpenter(Executive Officer, Director)Cornelis Been(Executive Officer, Director)

BoardSteven Hall(Director)Carole Nuechterlein(Director)inBernard Davitian(Director)

Co-investorsSanofi VenturesAtlas VentureHatteras Venture PartnersOmega FundsRoche Venture Fund

Orbis Medicinesorbismedicines.cominJan 2025 · $93M

Orbis Medicines is a drug discovery company developing orally bioavailable macrocycle drug candidates as alternatives to injectable biologics, targeting both intracellular and extracellular protein targets.

AI & Machine LearningBiotechDeep Tech

Co-investorsNew Enterprise Associates (NEA)ForbionNovo Holdings

Persist AIpersist-ai.cominSeries A · Apr 2023

Persist AI provides AI-driven formulation development services for pharmaceutical compounds, combining robotic lab automation with machine learning models to accelerate drug formulation optimization and reduce time-to-market.

AI & Machine LearningBiotechHealthtechMedical DevicesRoboticsSacramento, US

Karthik Raman(Founder)inChristopher Shelner(Founder)in

Co-investors2048 VenturesGlobal BrainGood AI CapitalJovonoPioneerSpero Ventures+5 more

Quarry Theraquarrythera.cominFeb 2025

Quarry Thera is a biotech developing oral small-molecule medicines based on induced-proximity pharmacology, using molecular glues and heterobifunctional compounds.

BiotechDeep TechNew Haven, US

Craig Crews(Co-Founder & Scientific Advisor)inMikael Dolsten, M.D., Ph.D.(Co-founder and Executive Chairman of the Board)Craig Crews, Ph.D.(Co-Founder & Scientific Advisor)Dan McHugh(Manager)Tim Shannon(CEO and Board Member)inJeanne Magram(Chief Scientific Officer)in

Co-investorsYosemiteF-Prime CapitalCanaan Partners

ReadCoorreadcoor.com𝕏Jan 2020 · $27M

Readcoor developed an in situ spatial transcriptomics platform using padlock probe rolling circle amplification chemistry to detect and map RNA transcripts across tissue sections, now offered as the Xenium In Situ platform.

BiotechDeep TechHardwareHealthtechCambridge, US

Evan Daugharthy(Cofounder)Richard Terry(Executive Officer, Director)

BoardYuh-Geng Tsay(Director)Victor Tong(Director)Thomas Grogan(Director)

Co-investorsDecheng CapitalLAVLilly Asia VenturesVivo Capital

Receptosreceptos.cominNov 2009Acquired

San Diego biopharmaceutical company developing GPCR-targeted immune-inflammatory drugs; acquired by Celgene for ~$7.2B in 2015.

BiotechSan Diego, US

Marcus Boehm(Executive Officer)inRobert Peach(Executive Officer)inRaymond Stevens(Director)inFaheem Hasnain(Executive Officer, Director)inJames Schmidt(Executive Officer)inChrysa Mineo(Executive Officer)in

Co-investorsARCH Venture PartnersOUP (Osage University Partners)Ridgeback CapitalVenrock

Verge Genomicsvergegenomics.comin𝕏Series C

Verge Labs builds AI models trained on multimodal human patient data to predict drug targets and patient populations for clinical development, primarily in neuroscience and central nervous system (CNS) disease.

AI & Machine LearningBiotechDeep TechDigital HealthHealthtechSan Francisco, US

Alice Zhang(Co-founder & CEO)inJason Chen(Cofounder)inEmily Ripka(Head of Product & Engineering)in

Co-investorsAgent CapitalALS Investment FundBOLD LongevityDraper AssociatesFitz Gate VenturesGreat Oaks Venture Capital+28 more

Viametviamet.com

Viamet provides a resource for people to organize questions and conduct research about medical travel, provider verification, care coordination, and health-related travel planning.

Digital HealthHealthtechTravel & HospitalityWellness & Fitness

Co-investorsAstellas Venture Management LLCHatteras Venture PartnersNovartis Venture FundWoodford Investment Management

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

CavionEsanexSymic Biomedical

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.